NEUROCRINE Trademark
Trademark Overview
On Thursday, September 21, 2023, a trademark application was filed for NEUROCRINE with the United States Patent and Trademark Office. The USPTO has given the NEUROCRINE trademark a serial number of 98191100. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, August 23, 2024. This trademark is owned by Neurocrine Biosciences, Inc.. The NEUROCRINE trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy, namely, Friedreich's ataxia, Parkinson's disease, GBA1-mediated diseases, and congenital birth defects; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia; Pharmaceutical preparations for human use for the treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephal...
Providing medical information; Providing medical information in the field of endocrine, hormonal, and genetic diseases, disorders, and conditions; Providing medical information in the field of gene therapy; providing medical information in the field of psychiatric, neurological, central nervous system, and movement diseases, disorders, and conditions; Providing medical information in the field of Huntington's Disease and chorea associated with Huntington's Disease
General Information
| Serial Number | 98191100 |
| Word Mark | NEUROCRINE |
| Filing Date | Thursday, September 21, 2023 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Friday, August 23, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 18, 2024 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment of endocrine, hormonal, and genetic diseases, disorders, and conditions; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy; Pharmaceutical preparations for human use for the prevention and treatment of diseases, disorders, and conditions by gene therapy, namely, Friedreich's ataxia, Parkinson's disease, GBA1-mediated diseases, and congenital birth defects; Pharmaceutical preparations for human use for the treatment of rare and orphan diseases, disorders, and conditions, namely, rare pediatric epilepsies, SCN8A developmental and epileptic encephalopathy, and congenital adrenal hyperplasia; Pharmaceutical preparations for human use for the treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuroendocrinological diseases, disorders, and conditions |
| Goods and Services | Providing medical information; Providing medical information in the field of endocrine, hormonal, and genetic diseases, disorders, and conditions; Providing medical information in the field of gene therapy; providing medical information in the field of psychiatric, neurological, central nervous system, and movement diseases, disorders, and conditions; Providing medical information in the field of Huntington's Disease and chorea associated with Huntington's Disease |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, October 8, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Sunday, October 8, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Neurocrine Biosciences, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
| Party Name | Neurocrine Biosciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92130 |
Trademark Events
| Event Date | Event Description |
| Monday, September 25, 2023 | NEW APPLICATION ENTERED |
| Wednesday, May 15, 2024 | ASSIGNED TO EXAMINER |
| Thursday, May 16, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 29, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, June 18, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, June 18, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 13, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Sunday, October 8, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, August 23, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, August 23, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, August 23, 2024 | SOU EXTENSION 1 GRANTED |
| Friday, August 23, 2024 | SOU EXTENSION 1 FILED |
| Tuesday, September 24, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Tuesday, September 24, 2024 | TEAS REQUEST TO DIVIDE RECEIVED |
| Wednesday, December 4, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Monday, December 9, 2024 | ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST |
